Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 03 2023
15 03 2023
Historique:
received:
30
08
2022
accepted:
03
03
2023
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
The immunogenicity of mRNA vaccines has not been well studied when compared to different vaccine modalities in the context of additional boosters. Here we show that longitudinal analysis reveals more sustained SARS-CoV-2 spike receptor-binding domain (RBD)-binding IgG titers with the breadth to antigenically distinct variants by the S-268019-b spike protein booster compared to the BNT162b2 mRNA homologous booster. The durability and breadth of RBD-angiotensin-converting enzyme 2 (ACE2) binding inhibitory antibodies are pronounced in the group without systemic adverse events (AEs) after the S-268019-b booster, leading to the elevated neutralizing activities against Omicron BA.1 and BA.5 variants in the stratified group. In contrast, BNT162b2 homologous booster elicited antibodies to spike N-terminal domain in proportion to the AE scores. High-dimensional immune profiling identifies early CD16
Identifiants
pubmed: 36922492
doi: 10.1038/s41467-023-37128-1
pii: 10.1038/s41467-023-37128-1
pmc: PMC10016167
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
BNT162 Vaccine
0
Immunoglobulin G
0
S-268019-b COVID-19 vaccine
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1451Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2018 Apr 11;13(4):e0193680
pubmed: 29641537
J Immunol. 1998 Mar 15;160(6):2637-44
pubmed: 9510161
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Immunity. 2015 Dec 15;43(6):1186-98
pubmed: 26682988
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Vaccine. 2019 Mar 28;37(14):2004-2015
pubmed: 30850240
Virol J. 2021 Jan 12;18(1):16
pubmed: 33435994
J Immunol. 2002 May 1;168(9):4756-63
pubmed: 11971026
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
J Exp Med. 2022 Aug 1;219(8):
pubmed: 35776090
Vaccine. 2021 Sep 24;39(40):5963-5967
pubmed: 34400017
J Immunol. 1975 Jan;114(1 Pt 2):394-8
pubmed: 1090658
Cell Rep. 2021 Aug 10;36(6):109504
pubmed: 34352226
Cell. 2021 Jul 22;184(15):3915-3935.e21
pubmed: 34174187
Sci Immunol. 2022 Apr 22;7(70):eabn8590
pubmed: 35113654
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
J Travel Med. 2022 May 31;29(3):
pubmed: 34918097
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Vaccine. 2022 Jul 30;40(32):4328-4333
pubmed: 35738968
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Vaccines (Basel). 2019 Dec 24;8(1):
pubmed: 31878161
Vaccine. 2022 Jun 15;40(27):3721-3726
pubmed: 35606235
Sci Transl Med. 2020 Jul 1;12(550):
pubmed: 32513867
Vaccine. 2013 Sep 13;31(40):4389-97
pubmed: 23856331
J Clin Lab Anal. 2021 Sep;35(9):e23937
pubmed: 34396586
Nature. 2023 Jan;613(7945):735-742
pubmed: 36473496
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Nat Immunol. 2009 Jan;10(1):116-125
pubmed: 19029902
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
J Exp Med. 2023 Feb 6;220(2):
pubmed: 36512034
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nature. 2021 Aug;596(7872):410-416
pubmed: 34252919
Aging Clin Exp Res. 2021 Nov;33(11):3151-3160
pubmed: 34652783
Int J Mol Sci. 2020 Nov 09;21(21):
pubmed: 33182504
Cell Rep Med. 2022 May 17;3(5):100631
pubmed: 35545084
Lancet. 2022 Jan 1;399(10319):36-49
pubmed: 34883053
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
mSphere. 2022 Apr 27;7(2):e0091521
pubmed: 35285250
Immunity. 2021 Dec 14;54(12):2877-2892.e7
pubmed: 34852217
Trends Immunol. 2015 Sep;36(9):536-46
pubmed: 26272882
Nat Immunol. 2004 Dec;5(12):1260-5
pubmed: 15531883
Nature. 2020 Apr;580(7805):576-577
pubmed: 32346146
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Biomed Pharmacother. 2022 Mar;147:112650
pubmed: 35066301
Sci Transl Med. 2021 Mar 3;13(583):
pubmed: 33658355
JAMA Netw Open. 2022 Aug 1;5(8):e2226335
pubmed: 35947380
JAMA. 2021 Apr 6;325(13):1318-1320
pubmed: 33635317
Nat Rev Drug Discov. 2020 Oct;19(10):667-668
pubmed: 32887942
Vaccine. 2022 Dec 12;40(52):7520-7525
pubmed: 36372670
Curr Drug Targets Inflamm Allergy. 2003 Mar;2(1):81-94
pubmed: 14561178
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Biomedicines. 2022 Jun 21;10(7):
pubmed: 35884770
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Immunity. 2021 Oct 12;54(10):2385-2398.e10
pubmed: 34508662
J Virol. 2010 Mar;84(6):2798-807
pubmed: 20053738
Vaccine. 2022 Jul 29;40(31):4231-4241
pubmed: 35691872
Vaccines (Basel). 2021 Jun 15;9(6):
pubmed: 34203652
Cell Rep. 2019 Feb 26;26(9):2307-2315.e5
pubmed: 30811982
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Sci Rep. 2018 Oct 24;8(1):15701
pubmed: 30356097
NPJ Vaccines. 2021 Apr 1;6(1):45
pubmed: 33795694
J Biol Chem. 2001 Jun 22;276(25):22779-87
pubmed: 11274187